AbbVie knows how to plan ahead.

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

Key market opportunities for SKYRIZI include its expansion across multiple indications such as psoriasis and IBD, showcasing best-in-class efficacy and strong clinical responses. Strategic positioning ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AbbVie’s Skyrizi again held onto its top spot on the TV ad spender leaderboard for the month of May, but overall spend across the stable top three is falling. Despite its lower spending, Skyrizi ...

AbbVie (ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...

AbbVie said on Monday it ⁠would ⁠buy Apogee Therapeutics for $10.9 billion, the ⁠company's largest buyout in more than five years, as it seeks to ​bolster its treatment pipeline for inflammatory ...

AbbVie ABBV continues to see strong momentum from Skyrizi and Rinvoq, its two blockbuster immunology medicines. Sales of both drugs not only mitigated the impact of continued erosion in legacy drug ...

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL-17 ...

AbbVie has won expanded European Commission approvals for its blockbuster autoimmune drug Skyrizi and its hepatitis C drug Maviret. AbbVie on Tuesday said Skyrizi is now approved in Europe for ...

NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI ® (risankizumab) for the treatment of children and ...